Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tcelna in Secondary Progressive Multiple Sclerosis
NCT01684761Phase 2Completed
- Sponsor
- Opexa Therapeutics
- Start
- Aug 2012
- Primary completion
- Oct 2016
- Modality
- Native Immune Cells, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of tovaxin in secondary-progressive multiple sclerosis (SPMS), sponsored by Opexa Therapeutics. Started Aug 2012; status: completed.
02
Drugs
tovaxin
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT01684761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01684761.